DE69840908D1 - Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe - Google Patents

Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe

Info

Publication number
DE69840908D1
DE69840908D1 DE69840908T DE69840908T DE69840908D1 DE 69840908 D1 DE69840908 D1 DE 69840908D1 DE 69840908 T DE69840908 T DE 69840908T DE 69840908 T DE69840908 T DE 69840908T DE 69840908 D1 DE69840908 D1 DE 69840908D1
Authority
DE
Germany
Prior art keywords
prostaglandin
derivatives
composition
delayed delivery
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840908T
Other languages
English (en)
Inventor
Michio Hara
Yasuhide Horiuchi
Fuminori Tamura
Keishi Yamasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of DE69840908D1 publication Critical patent/DE69840908D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69840908T 1997-03-14 1998-03-13 Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe Expired - Lifetime DE69840908D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6150197 1997-03-14
PCT/JP1998/001057 WO1998041210A1 (fr) 1997-03-14 1998-03-13 Preparation de derive de prostaglandine i a liberation prolongee

Publications (1)

Publication Number Publication Date
DE69840908D1 true DE69840908D1 (de) 2009-07-30

Family

ID=13172913

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840908T Expired - Lifetime DE69840908D1 (de) 1997-03-14 1998-03-13 Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe

Country Status (13)

Country Link
US (1) US6656502B1 (de)
EP (1) EP0947196B1 (de)
JP (1) JP3744941B2 (de)
CN (1) CN100502877C (de)
AT (1) ATE433753T1 (de)
AU (1) AU6310898A (de)
CA (1) CA2255052C (de)
DE (1) DE69840908D1 (de)
DK (1) DK0947196T3 (de)
ES (1) ES2328191T3 (de)
NO (1) NO985299L (de)
PT (1) PT947196E (de)
WO (1) WO1998041210A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092760A1 (en) * 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
AU2003296852A1 (en) * 2002-09-18 2004-05-04 Elan Corporation, Plc Multiparticulate modified release composition comprising beraprost
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
ATE341312T1 (de) * 2003-05-20 2006-10-15 Ethypharm Sa Orale pharmazeutische zusammensetzung mit verzögerter freisetzung
CN101780092B (zh) 2003-05-22 2012-07-04 联合治疗公司 化合物和释放前列环素类似物的方法
US7063862B2 (en) 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US9205047B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
EA023720B1 (ru) * 2009-08-07 2016-07-29 Сифарм Сарл Композиция для лечения муковисцидоза
US8912192B2 (en) 2010-02-12 2014-12-16 Taisho Pharmaceutical Co., Ltd Extended release preparation
CN106822013B (zh) * 2015-11-30 2020-05-12 北京泰德制药股份有限公司 前列环素类似物缓释制剂
CN107496348A (zh) * 2017-08-28 2017-12-22 天津昂赛细胞基因工程有限公司 一种用于组织损伤修复的水凝胶及制备方法
MX2020004962A (es) 2017-11-16 2020-08-27 Nippon Shinyaku Co Ltd Preparacion de liberacion controlada.
CN115989031A (zh) 2019-12-23 2023-04-18 东丽株式会社 用于抑制透析转化或肾死亡的药剂
TW202317089A (zh) 2021-06-16 2023-05-01 日商東麗股份有限公司 罹患慢性腎臟病的貓的治療方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
JPH0759521B2 (ja) 1985-09-30 1995-06-28 藤沢薬品工業株式会社 ゲル層形成型徐放性製剤
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
JPH02218621A (ja) 1989-02-20 1990-08-31 Nippon Chemiphar Co Ltd 徐放性製剤
JPH02225416A (ja) 1989-02-28 1990-09-07 Toray Ind Inc ５，６，７―トリノル―４，８―インタ―ｍ―フェニレンＰＧＩ↓２誘導体の経口用製剤
JP3007387B2 (ja) 1990-07-16 2000-02-07 エーザイ株式会社 徐放性製剤用基剤粉末
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form

Also Published As

Publication number Publication date
CN1219132A (zh) 1999-06-09
CA2255052C (en) 2009-09-15
US6656502B1 (en) 2003-12-02
ATE433753T1 (de) 2009-07-15
PT947196E (pt) 2009-09-24
EP0947196A4 (de) 2005-01-12
CN100502877C (zh) 2009-06-24
EP0947196A1 (de) 1999-10-06
NO985299D0 (no) 1998-11-13
ES2328191T3 (es) 2009-11-10
CA2255052A1 (en) 1998-09-24
DK0947196T3 (da) 2009-10-12
WO1998041210A1 (fr) 1998-09-24
EP0947196B1 (de) 2009-06-17
NO985299L (no) 1999-01-14
JP3744941B2 (ja) 2006-02-15
AU6310898A (en) 1998-10-12

Similar Documents

Publication Publication Date Title
DE69840908D1 (de) Zusammensetzung von prostaglandin-i-derivaten mit verzoegerter abgabe
NO890075D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazoler.
EP0668073A3 (de) Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe.
AU3990797A (en) Sustained release formulation
DE69435295D1 (de) Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe
DE69101291D1 (de) Zusammensetzung zur kontrollierten Abgabe von Medikamenten.
DE60038097D1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
DE69307977T2 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
FI101227B1 (fi) Menetelmä farmaseuttisesti aktiivisten 4-desoksi-4-epipodofyllotoksiinijohdannaisten valmistamiseksi
CA2344053A1 (en) Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
DK545889D0 (da) Anti-human-immundefektvirus-praeparat
IT1284604B1 (it) Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
DE69813263T2 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
DK0540813T3 (da) Acetazolamid-præparat med vedvarende afgift af aktivt stof
NO950950L (no) Farmasöytisk preparat
AU1042888A (en) Pain-killer
BR0010449A (pt) 14beta-h-esteróis, composições farmacêuticas que compreendem os mesmos e uso destes derivados para a preparação de medicamentos reguladores da meiose
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
DE60026559D1 (de) Arzneimittel gegen essstörungen
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
MX9605633A (es) Composicion farmaceutica, metodo y dispositivo para prevenir o tratar resequedad de los ojos o enfermedad ocasionada por la misma.
ITRM920173A1 (it) Composizione a base di ibuprofen per uso orale.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition